Previous Close | 18.33 |
Open | 18.41 |
Bid | 15.00 x 4000 |
Ask | 21.00 x 1300 |
Day's Range | 17.83 - 19.18 |
52 Week Range | 10.41 - 21.29 |
Volume | |
Avg. Volume | 640,195 |
Market Cap | 1.233B |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.99 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 35.88 |
Subscribe to Yahoo Finance Plus to view Fair Value for KURA
Kura Oncology had its Relative Strength (RS) Rating stock upgraded from 81 to 93 Thursday. Over 100 years of market history shows that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest price moves. Is Kura Oncology Stock A Buy?
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. “As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team” said Jonathan Violin, Ph.D., Viridia
Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercializati